ReviewInfection ecology & epidemiology2021
Is Africa ready for mobile colistin resistance threat?
Review in Infection ecology & epidemiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 18 citations in OpenAlex.
- Mapping the resistance landscape: A large-scale study of polymyxin-resistant pathogens circulating in low-and middle-income countries.Research square · 2026Article
- Asymptomatic faecal carriage of multidrug-resistant and carbapenemase-producing Gram-negative bacteria among inpatients and outpatients in a Kenyan county referral hospital: a cross-sectional study.BMC infectious diseases · 2026Article
- The colistin resistance pandemic: A dual threat from plasmid-encoded mobilised colistin resistance genes and chromosomal mutations.African journal of laboratory medicine · 2026Review
- Regional Genomic and Phylogenomic Insights into Multidrug and Colistin-Resistant Klebsiella pneumoniae Strains from Tanzania, Kenya, Uganda, and Ethiopia.Current microbiology · 2025Article
- Low occurrence and clonal relatedness of multi-drug resistantFrontiers in veterinary science · 2025Article
- Prevalence of colistin-resistantHeliyon · 2024Article
- Characterisation of colistin resistance in Gram-negative microbiota of pregnant women and neonates in Nigeria.Nature communications · 2024Article
- EFFECT OFAfrican journal of infectious diseases · 2024Article
- Mobile Colistin Resistance (Antibiotics (Basel, Switzerland) · 2023Review
- Colistin Resistance Genes in Broiler Chickens in Tunisia.Animals : an open access journal from MDPI · 2023Article
- Epidemiology and Traits of Mobile Colistin Resistance (Microorganisms · 2022Review
- Microbiological Characterisation of Community-Acquired Urinary Tract Infections in Bagamoyo, Tanzania: A Prospective Study.Tropical medicine and infectious disease · 2022Article
- Molecular Detection of Integrons, Colistin andMicroorganisms · 2022Article
- Mobile Tigecycline Resistance: An Emerging Health Catastrophe Requiring Urgent One Health Global Intervention.Frontiers in microbiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial resistance is a growing public health problem and a threat to effective treatment and prevention of an array of infections caused by bacteria. Africa is already faced with many socio-economic and health crises. Many countries in Africa can seldom boast of a standardized health care facility comparable to those in developed countries. Yet, the non-therapeutic use of COL has been banned in developed countries. However, in Africa, except for South Africa, COL is an over-the-counter (OTC) medication sold and dispensed by non-professionals/without a veterinarian's supervision. The ban of non-therapeutic COL in developed countries has proven to reduce the development of mobile colistin resistance (MCR) in humans and animals. The unregulated use of COL has been proven to select pathogenic and commensal bacteria resistance. A transmissible plasmid-mediated colistin determinant, mobile COL resistance (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.